Product image of Ngenla (Somatrogon) supplied by GNH India

Ngenla

Active Ingredient:
Somatrogon
Origin:
EU

Ngenla (Somatrogon)

Somatrogon, the active ingredient in Ngenla, is a growth hormone analog presented as a subcutaneous injection for subcutaneous use. It is indicated for the treatment of growth hormone deficiency in children, helping to support normal linear growth and metabolic development.

GNH India supplies Ngenla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to support pediatric endocrine care across global markets. Our distribution network ensures reliable delivery and cold‑chain handling where required.

Manufacturer / TM Owner

Pfizer Europe Ma Eeig

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ngenla is a growth hormone analog used to address conditions caused by insufficient endogenous growth hormone.

  • Growth hormone deficiency in children: promotes linear growth and improves IGF‑1 levels.
  • Short stature due to GH deficiency: supports height gain during the growth period.
  • Metabolic effects of GH deficiency: helps normalize protein, lipid and carbohydrate metabolism.

How It Works

  • Somatrogon binds to growth hormone receptors on target cells, activating the JAK2‑STAT5 signaling cascade. This stimulates hepatic production of insulin‑like growth factor‑1 (IGF‑1), which mediates the anabolic and growth‑promoting effects on bone, muscle and other tissues, while also influencing metabolic pathways.

Side Effects

Somatrogon may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects

  • Injection site reactions: redness, swelling or pain at the injection site.
  • Headache: mild to moderate intensity.
  • Abdominal discomfort: nausea or stomach pain.
  • Joint pain: arthralgia in limbs.
  • Peripheral edema: mild swelling of hands or feet.
  • Fatigue: feeling unusually tired.

Serious or Rare Side Effects

  • Intracranial hypertension: symptoms include severe headache and visual changes.
  • Slipped epiphysis: risk of growth plate displacement.
  • Severe allergic reaction: rash, itching, swelling, or anaphylaxis.
  • Abnormal glucose metabolism: hyperglycemia or impaired tolerance.
  • Cardiomyopathy: rare heart muscle dysfunction.
  • Tumor progression: potential acceleration of existing malignancies.

Precautions & Warnings

Prior to initiating therapy, clinicians should evaluate patients for specific risk factors and monitor ongoing safety.

  • IGF‑1 monitoring: adjust dose to maintain target IGF‑1 range.
  • Intracranial hypertension: watch for persistent headaches or visual disturbances.
  • Glucose tolerance: assess fasting glucose and HbA1c periodically.
  • Skeletal health: screen for scoliosis or slipped epiphysis in rapidly growing children.
  • Hypersensitivity: discontinue if severe allergic reaction occurs.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Somatrogon may interact with other agents that affect growth hormone pathways or glucose metabolism.

Major Interactions (Avoid)

  • High‑dose glucocorticoids: may blunt the anabolic response.
  • Insulin or oral hypoglycemics: increased risk of hypoglycemia.
  • Oral estrogen therapy: can elevate IGF‑1 levels excessively.

Moderate Interactions (Monitor Closely)

  • Other growth hormone analogs: additive effects on IGF‑1.
  • Thyroid hormone replacement: may require dose adjustment.
  • Diuretics: can exacerbate peripheral edema.

Frequently Asked Questions

Ngenla contains somatrogon, a growth hormone analog prescribed to treat growth hormone deficiency in children. By restoring normal growth hormone activity, it helps promote linear growth, improve height velocity, and support metabolic functions during childhood development.

Somatrogon binds to the growth hormone receptor, triggering the JAK2‑STAT5 pathway. This leads to increased hepatic production of insulin‑like growth factor‑1 (IGF‑1), which drives bone growth, protein synthesis, and metabolic regulation throughout the body.

The dose of Ngenla is individualized. A qualified prescriber determines the appropriate amount, frequency and titration schedule based on the child’s age, weight, IGF‑1 levels and clinical response.

Safety of somatrogon in pregnant or nursing women has not been established. It is generally reserved for pediatric patients, and use in women of child‑bearing potential should be considered only if the potential benefit outweighs any potential risk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Ngenla (somatrogon) is a long‑acting growth hormone analog that requires less frequent subcutaneous injections compared with daily recombinant human growth hormone products. This can improve adherence while delivering comparable IGF‑1 responses and growth outcomes.

Ngenla should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Once reconstituted, use within the time frame specified in the product label and keep the solution refrigerated.

Ngenla is given as a subcutaneous injection, typically into the thigh or abdomen. The injection site should be rotated to minimize local reactions, and the dose is administered by a healthcare professional or trained caregiver according to the prescriber’s instructions.

Serious risks include intracranial hypertension, slipped epiphysis, severe allergic reactions, abnormal glucose metabolism and potential acceleration of existing tumors. Patients should be monitored regularly for these conditions, and therapy should be stopped if any serious adverse event occurs.

Ngenla is contraindicated in patients with known hypersensitivity to somatrogon or any excipients, in children with active malignancies, and in those with uncontrolled diabetes or severe intracranial hypertension. A thorough medical assessment is required before initiating therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Somatrogon

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT